Assessment Value of Combined Detection of Hepatointestinal Calcoprotein and Tumor Markers in Staging of Gastric Cancer and its Relationship with Clinicopathological Features
ZHAO Ning, MA Wei
Suqian Hospital of Traditional Chinese Medicine, Jiangsu Suqian 223800, China
Abstract：Objective: To analyze the value of detection of hepatoenteral calcoprotein(CDH17) combined with tumor markers in the evaluation of gastric cancer staging and its relationship with clinicopathological features. Methods: 147 patien ts with gastric cancer who according to the standard of TNM staging gastric carcinoma was divided into 8 cases of stage Ⅰperiod, 13 cases of Ⅱperiod, 57 cases of Ⅲ period, 69 cases of Ⅳ period; At the same time, 171 patients with benign gastric lesions and 130 healthy patients were selected as the control group. serum CDH17 and tumor marker levels, positive tissue expression rates in each group were compared,serum CDH17 and tumor markers of each group were compared, and their diagnostic value for gastric cancer staging was also compared. Results: CDH17 and serum tumor marker levels in gastric cancer group were higher than that of benign gastric lesion group, gastric benign lesion group were higher than the control group, there was a statistically significant difference (P<0.01). CDH17 area under the curve was 0.597, CEA area under the curve was 0.508, CA50 area under the curve was 0.689, the area under the curve was CA199, CA242 0.601 area under the curve was 0.553, CA724 area under the curve was 0.725, combined determination of area under the curve was 0.810, the joint detection area under the curve was higher than a single index. Conclusion: The expression of CDH17 and tumor markers in gastric cancer is correlated with the stage of gastric cancer, which is helpful for the diagnosis of gastric cancer and the evaluation of malignant biological behavior. The combined monitoring can make up for the deficiency of individual indicators and has high clinical application value.
赵宁, 马威. 肝肠钙粘蛋白及肿瘤标志物联合检测对胃癌分期的评估价值及与临床病理特征的关系[J]. 河北医学, 2019, 25(9): 1422-1426.
ZHAO Ning, MA Wei. Assessment Value of Combined Detection of Hepatointestinal Calcoprotein and Tumor Markers in Staging of Gastric Cancer and its Relationship with Clinicopathological Features. HeBei Med, 2019, 25(9): 1422-1426.
[1] Kwak M, Kim C. Disparities by age, sex, tumor stage, diagnosis path, and area-level socioeconomic status in survival time for major cancers: results from the busan cancer registry[J].Korean Med Sci, 2017, 32(12): 1974~1983. [2] Lu jun, Zheng chaohui, Cao longlong, et al. Validation of the American joint commission on cancer (8th edition) changes for patients with stage III gastric cancer: survival analysis of a large series from a specialized eastern center[J]. Cancer Med, 2017, 6(10): 2179~2187. [3] 周萍,王聪,赵车冬,等.CEA、CA199、CA125、CA724联合检测对胃癌的临床诊断价值[J].实用癌症杂志,2017,32(9):1427~1429. [4] 吴巧斌,王飞,李建国.肝肠钙黏着蛋白的表达与消化系统肿瘤关系的研究现状[J].医学综述,2016,22(12):2292~2295. [5] Fehim S, Bouhaous R, Diaf M, et al. Epidemiological profile of gastric cancer in the northwestern region of Algeria: about 116 cases[J].Gastrointest Oncol, 2017, 8(4): 659~664. [6] 艾特热白·吾甫尔.赵瑾,陈卫刚.CDH17,CA24-2,CA72-4与CEA联合检测对胃癌诊断价值的研究[J].胃肠病学和肝病学杂志,2016,25(11):1233~1235. [7] 李蒙,吴玖斌,张培彤.E-钙黏蛋白,N-钙黏蛋白及波形蛋白在肿瘤转移中应用的研究进展[J].肿瘤研究与临床,2016,28(2):132~136. [8] 许伟龙,南永刚,李林,等.胃蛋白酶原联合多种肿瘤标志物检测在胃癌早期诊断中的价值[J].现代肿瘤医学,2017,25(16):2622~2625. [9] 袁建明,刘涛,沈东杰,等.血清STAT1和肿瘤标志物联合检测对胃癌的诊断价值[J].生物医学工程与临床,2017,21(4):425~428. [10] 施城东,樊卫.肿瘤标志物CA19-9、CEA、CA242、CA125和AFP评估胃癌化疗疗效的检验分析[J].国际检验医学杂志,2016,37(13):1777~1779. [11] 杜娟,杨磊,席妍,等.血清胃蛋白酶原及肿瘤标志物联合检测在老年胃癌诊断中的意义[J].中国医药导报,2015,12(32):97~99.
2019, Vol. 25 
冀公网安备13080202000677号